Report #2865240

Received Oct 13, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Female
Age: Age unknown
State: CA
Recovered: Unknown
Vaccinated: Sep 10, 2025
Onset: Sep 10, 2025
Days to onset: 0
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
VARZOS	ZOSTER (SHINGRIX)	GLAXOSMITHKLINE BIOLOGICALS	2	94J5E	—

Symptoms (1)

Inappropriate schedule of product administration

Symptom narrative

Less than recommended interval; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too short in a 79-year-old female patient who received Herpes zoster (Shingrix) (batch number 94J5E, expiry date 02-MAY-2027) for prophylaxis. Concomitant products included Herpes zoster (Shingrix). On 10-SEP-2025, the patient received the 2nd dose of Shingrix. On 10-SEP-2025, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too short (Verbatim: Less than recommended interval). The outcome of the drug dose administration interval too short was not applicable. Additional Information: GSK receipt date: 06-OCT-2025 On 26-AUG-2025, The patient received 1st dose of Shingrix (batch number 342XP and expiry date 28-APR-2027). The patient received 2nd dose of Shingrix at lesser than the recommended interval which led to shortening of vaccination schedule.